anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Proposal for participation to the holders of parental authority of newborns eligible within 72 hours after the birth of the child. If acceptance of participation, the newborn will be included in the study. Participation in the study will not affect the medical care of the child. Participation in the study will consist of: a collection of data including the child sleeping mode, complete a questionnaire covering the child sleeping habits to motherhood and home during the 1st month of life. Information on the habits of sleeping in the home of the child will be collected via a phone call by an investigator. Inclusions will be held over 2 periods: one before and one after the completion of training of health care personnel regarding the sleeping of infants nursing staff training will consist of oral information by the investigative team and written information...
Background/Objectives: Hypertension and its associated complications, such as cardiac remodeling and dysfunction, continue to impose a significant burden on global healthcare. Nutritional interventions have been recognized as playing a crucial role in addressing this devastating condition termed a 'silent killer'. Plant-based proteins could potentially be utilized as a non-pharmacological strategy to combat hypertension and its related risk factors. In this study, we investigated the efficacy of an oat protein diet in managing hypertension and cardiac abnormalities. Methods: Four-week-old male spontaneously hypertensive rats (SHRs) and Wistar-Kyoto (WKY) rats were fed a regular diet with casein as a protein source or an oat-protein-based diet for 16 weeks. Twenty-week-old male SHRs showed high blood pressure (BP), cardiac remodeling, cardiac dysfunction, higher levels of markers of oxidative stress [malondialdehyde (MDA)] and inflammation [tumor necrosis factor-α (TNF-α)], as well as lower levels of a marker of vascular function (nitric oxide). Results: The oat protein diet was able to significantly lower high BP, prevent cardiac remodeling and dysfunction, improve the levels of nitric oxide, and reduce the levels of TNF-α. Oat protein, after in vitro gastrointestinal digestion, also exhibited angiotensin-converting enzyme inhibition and significantly higher antioxidant activity than casein when assessed with the 2,2-diphenyl-1-picrylhydrazyl and the iron-chelating assays in vitro.Conclusions: oat protein lowers BP and prevents cardiac remodeling and dysfunction partly via improving the levels of nitric oxide and TNF-αin SHRs. Its high antioxidant potential could contribute to the observed cardiovascular effects.
The present invention concerns the role of IGFBP-2 in cancer. Cancers that are dependent on IGFBP-2 would benefit from therapies targeting IGFBP-2. The invention discloses methods for inhibiting IGFBP-2 dependent cancers by modulating IGFBP-2 activity. Modulation can be achieved by decreasing the amounts of IGFBP-2 protein or IGFBP-2 activity, as well as other polypeptides that interact with or modify IGFBP-2. Preferred modulators of IGFBP-2 include antibodies specific for IGFBP-2 and antisense or ribozymes specific for IGFBP-2 nucleic acid. These modulators are useful for treating cancers derived from any tissue, with cancer of the prostate being preferred. Methods of treating a subject with cancer are disclosed as well as compositions of IGFBP-2 modulators and kits containing such modulators.
Post-traumatic stress disorder (PTSD), a chronic, debilitating condition, is a growing public health concern as the Canadian population has the highest PTSD prevalence worldwide (9.2%; 3.7 million people). PTSD is linked with several co-morbid mental health disorders (e.g., depression) and increased risk of chronic disease (e.g., cardiovascular disease, obesity) which presents challenges as far as the determination of appropriate treatment. Adjunctive treatment approaches for PTSD that include somatic-sensory body awareness (e.g., mindfulness, yoga) have been shown to be viable treatment options to reduce stress-related symptoms and enhance emotion regulation. Online treatment deliveries for mental health disorders demonstrate similar reductions in self-reported symptoms as face-to-face methods and emphasize accessibility, reduced costs, and enhanced appeal to certain demographic groups. A target population at risk of untreated PTSD symptoms that may benefit from an online treatment is young adults, 18-34 yrs., who have experienced trauma during pre-adult development. No known clinical trial (CT) has addressed the effectiveness of a brief (8-week) online trauma-informed yoga intervention using both self-report and objective psychophysiology measures. This study evaluates such an intervention in terms of changes in self-reported PTSD symptoms and objectively measured biomarkers of autonomic regulation via pupil dilation and heart-rate-variability (HRV) following an 8-week single-arm experimental design. It is hypothesized that results will demonstrate clinically significant reductions of: 1) PTSD total symptom severity; 2) statistically significant reductions in pupil dilation and; 3) significant increases in HRV at post-intervention. This is the first study to examine objective markers of autonomic regulation in an at-risk population using multiple novel technologies (e.g., Eye Tracking Glasses, HRV) that compare two theoretically-linked measures (e.g., HRV, Pupillometry). Comparisons of psychophysiology data with a cross-sectional convenience sample with no history of clinical PTSD or mental health conditions are made
Risk Summary

There are no studies of riluzole in pregnant women, and case reports have been inadequate to inform the drug-associated risk. The background risk for major birth defects and miscarriage in patients with amyotrophic lateral sclerosis is unknown. In the U.S. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

In studies in which riluzole was administered orally to pregnant animals, developmental toxicity (decreased embryofetal/offspring viability, growth, and functional development) was observed at clinically relevant doses [see Data]. Based on these results, women should be advised of a possible risk to the fetus associated with use of riluzole during pregnancy.

Data

     Animal Data
    Oral administration of riluzole (3, 9, or 27 mg/kg/day) to pregnant rats during the period of organogenesis resulted in decreases in fetal growth (body weight and length) at the high dose. The mid dose, a no-effect dose for embryofetal developmental toxicity, is approximately equal to the recommended human daily dose (RHDD, 100 mg) on a mg/m2 basis. When riluzole was administered orally (3, 10, or 60 mg/kg/day) to pregnant rabbits during the period of organogenesis, embryofetal mortality was increased at the high dose and fetal body weight was decreased and morphological variations increased at all but the lowest dose tested. The no-effect dose (3 mg/kg/day) for embryofetal developmental toxicity is less than the RHDD on a mg/m2 basis. Maternal toxicity was observed at the highest dose tested in rat and rabbit.
    When riluzole was orally administered (3, 8, or 15 mg/kg/day) to male and female rats prior to and during mating and to female rats throughout gestation and lactation, increased embryofetal mortality and decreased postnatal offspring viability, growth, and functional development were observed at the high dose. The mid dose, a no-effect dose for pre-and postnatal developmental toxicity, is approximately equal to the RHDD on a mg/m2 basis.
Ototoxicity is a common side effect of cisplatin cancer treatment, potentially leading to hearing loss. This study demonstrated the significant protective activity of Acanthopanax sessiliflorus (A. sessiliflorus) leaves against cisplatin-induced ototoxicity (CIO), investigated the active compounds, and elucidated their mechanisms in countering CIO. UPLC-Q/TOF-MS analysis identified 79 compounds. Network pharmacology and activity screening determined that chiisanoside (CSS) plays a crucial role in combating CIO. Transcriptomics combined with network pharmacology analysis and experiments revealed that CSS activates the Dock1/PIP5K1A pathway to suppress the actin-severing protein gelsolin, protecting hair cells from cisplatin-induced cytoskeleton damage. CSS also activates the SLC7A11/GPX4 pathway via TGFBR2, reducing lipid peroxidation and intracellular iron accumulation to suppress cisplatin-induced ferroptosis. This study discovers that the major component CSS in A. sessiliflorus leaves reverses CIO by regulating actin homeostasis via Dock1 and inhibiting ferroptosis through TGFBR2, providing a theoretical basis for expanding CIO treatment targets and related drug development.
NEW MATERIAL:A compound of formula I (Ser is L-serine residue; Asp is L-aspartic acid residue; Gly is glycine residue; Lys is L-lysine residue). USE:An antiallergic agent, a vasodilator and an immunoregulator. PREPARATION:Dehydration condensation is carried out between a glycine derivative of formula Boc-Gly-OH (Boc is t-butyloxycarbonyl) and an L-lysine derivative of formula II (Z is benzyloxycarbonyl; Bzl is benzyl) to obtain a compound of formula Boc-Gly-Lys(Z)-OBzl. The Boc group is then eliminated using an acid and an L-aspartic acid derivative of formula Boc-Asp(OBzl)-OH is added thereto to obtain formula Boc-Asp(OBzl)-Gly-Lys(Z)-OBzl by dehydration condensation. The Boc group is subsequently eliminated using an acid and an L-serine derivative of formula Z-Ser-OH is then added thereto for dehydration and condensation. Catalytic reduction is then carrier out.
FIELD: medicine. ^ SUBSTANCE: invention refers to drugs and concerns a nasal composition for treating fungi induced rhinosinusitis in a mammal where said composition contains a water suspension containing: (a) 1-700 mcg of a suspended solid steroidal anti-inflammatory agent. The steroidal anti-inflammatory agent represents fluticasone or its pharmaceutically acceptable salt, an ester, enolnyj a simple aether, an enol aether, an acid or a basis where said steroidal anti-inflammatory agent has a particle size distribution profile specified in the patent claim; (b) an antifungal agent where an amount of the antifungal agent is 0.5 to 150 mg. Said composition is applicable for introducing in a nasal-paranasal mucosa. Also, disclosed are a nasal composition for treating fungi induced rhinosinusitis, containing beclomethasone as the steroidal anti-inflammatory agent, and a method of treating fungi induced rhinosinusitis. ^ EFFECT: improved bioavailability of fluticasone and beclomethasone due to a certain particle size distribution. ^ 55 cl, 2 tbl, 5 ex
The aim is to include 30 patients with peanut allergy. Those patients will undergo diagnostic food challenges (incremental doses) while blood will be samples before, during and after the testing. The patients will receive standard of care during and after the challenge. Allergic symptoms will be treated according to established guidelines.
Early brain injury (EBI) after aneurysmal subarachnoid hemorrhage (aSAH) has been increasingly recognized as a risk factor for delayed cerebral ischemia (DCI). While several clinical and radiological EBI biomarkers have been identified, no tool for systematic assessment of EBI severity has been established so far. This study aimed to develop an EBI grading system based on clinical signs and neuroimaging for estimation of EBI severity at admission. This is a retrospective observational study assessing imaging parameters (intracranial blood amount, global cerebral edema (GCE)), and clinical signs (persistent loss of consciousness [LOC]) representative for EBI. The intracranial blood amount was semi-quantitatively assessed. One point was added for GCE and LOC, respectively. All points were summed up resulting in an EBI grading ranging from 1 to 5. The estimated EBI severity was correlated with progressive GCE requiring decompressive hemicraniectomy (DHC), DCI-associated infarction, and outcome according to the modified Rankin scale (mRS) at 3-month-follow up. A consecutive cohort including 324 aSAH-patients with a mean age of 55.9 years, was analyzed. The probability of developing progressive GCE was 9% for EBI grade 1, 28% for EBI grade 2, 43% for EBI grade 3, 61% for EBI grade 4, and 89% for EBI grade 5. The EBI grading correlated significantly with the need for DHC (r = 0.25, p < 0.0001), delayed infarction (r = 0.30, p < 0.0001), and outcome (r = 0.31, p < 0.0001). An EBI grading based on clinical and imaging parameters allowed an early systematic estimation of EBI severity with a higher EBI grade associated not only with a progressive GCE but also with DCI and poor outcome.
PURPOSE: A make-up cosmetic composition containing titanium dioxide is provided to prevent white cloudy phenomenon and to express natural make-up. CONSTITUTION: A make-up cosmetic composition comprises capsules containing 20-80 weight% of titanium dioxide. The capsule contains 1.0-40.0 weight% based on total weight of the composition. The particle diameter of the capsule is 200nm-3um. The particle diameter of titanium dioxide is 10-100 nm. The capsule further contains 0.1-30 weight% of ferric oxide. The composition is formulated in face powder, compact, powder foundation, two way cake, liquid foundation, cream foundation, or make-up base.
Provided is an oxidative reduction potential (ORP) water solution that is stable for at least twenty-four hours and methods of using the solution. The present invention provides a method of preventing or treating a condition in a patient, which method comprises administering a therapeutically effective amount of the ORP water solution. Additionally provided is a method of treating impaired or damaged tissue, which method comprises contacting the tissue with a therapeutically effective amount of the ORP water solution. Further provided is a method of disinfecting a surface, which method comprises contacting the surface with an anti- infective amount of the ORP water solution. A process for producing an ORP water solution is also provided. ® KIPO & WIPO 2007
Topical compsn. for use on the scalp. for treatment of seborrheic alopecia, dandruff, greasy hair and calvities contains (a) at least one aromatic cpd. having one or more quinonic or phenolic gps. opt. in the form of its salts or other derivs. e.g. substd. by halo and/or alkyl gps. and/or (b) at least one inhibitor of enzymatic reactive -SH gps. chosen from mercury salts and a liquid vehicle. The compsn. is used to treat seborrhic alopecia, dandruff, greasy hair and calvities which inhibits scalp enzymes without the inconvenience of using steroids. The preferred active cpd. is chosen from o-benzoquinone, p-benzoquinone, menadione (2-methyl-1,4-naphthoquinone), menadione sodium bisulphite, potassium o-oxyquinoline sulphate or sodium merthiolate (Thimerosal). The vehicle usually comprises water and/or a lower alkanol and contains 1-2.5 wt.% of active cpd.
This review aimed to assess the effectiveness of the eutectic mixture of local anaesthetics (EMLA) cream in the management of arteriovenous fistula (AVF) needle insertion pain in adult patients undergoing haemodialysis (HD) compared with other alternative interventions. The main search was conducted in November 2020 and updated in December 2021. In the search strategy, keywords and synonyms were used and multiple databases were searched with no date limitation to ensure a comprehensive search that would yield all studies relevant to the review and minimise location bias. A total of 209 studies were found in this search and filtered. After filtering through these studies, only five studies were finally included in the review. EMLA-cream was found to be effective in reducing AVF needle insertion pain among adult patients undergoing HD. Despite EMLA cream's effectiveness in reducing HD needle insertion pain and its fewer side effects, the findings of the included studies should be interpreted with caution, as there are some limitations, and further research is required.
PURPOSE: To assess the effectiveness and safety of topical vancomycin powder (VP) in preventing surgical site infections (SSIs) in spinal deformity surgeries.
METHODS: A literature search was conducted on Web of Science, PubMed, and Cochrane Library databases for comparative studies of VP in spinal deformity surgeries published before February 2024. Two reviewers independently screened eligible articles based on the inclusion and exclusion criteria, assessed study quality, and extracted data. Data analysis was performed using Review Manager 5.4 software.
RESULTS: Of all 143 papers screened, a meta-analysis was conducted on 10 articles, which included a total of 8,166 surgeries. The results of the meta-analysis indicated that the incidence of deep SSI in VP group was 0.28 times that in non-VP group (p < 0.001). In the subgroup analysis, VP treatment significantly reduced the risk of deep SSI in both adult spinal deformity (ASD) (RR 0.40, 95% CI 0.21-0.77, p = 0.006) and pediatric scoliosis (PS) (RR 0.25, 95% CI 0.16-0.38, p < 0.001) surgeries. However, this effect was not observed in neuromuscular scoliosis (NMS) patients (RR 0.66, 95% CI 0.26-1.66, p = 0.38). Bacterial culture results indicated that VP treatment significantly reduced polymicrobial infections (p = 0.007) and gram-positive infections (p = 0.001).
CONCLUSION: From the literature available at present, VP was associated with reduced deep SSIs rates in spinal deformity patients. However, particular attention should be paid to the lack of the effectiveness of VP in NMS patients. The current literature did not report local cytotoxicity or renal toxicity related to VP in spinal deformity patients.
The invention belongs to a traditional Chinese medicine, and specifically a traditional Chinese medicine used for treating asthma. The medicine is characterized in that the medicine is prepared from the components of, by weight: 2-4 parts of dried hippocampus, and 5-7 parts of ligusticum. According to the invention, high-quality dried hippocampus is finely selected, and ligusticum is soaked for 30min; the materials are decocted with water; a juice is obtained, and slag is removed; decoction is repeated once; juices obtained in the two times are mixed, and 150-200ml of medicine liquid is obtained. One preparation is taken a day, and is taken for 2 times separately. The medicine is provided according to a differentiation theory of Chinese medical science, and has the advantages of simple component, easy-to-obtain material, low cost, high treatment effect, and no toxic or side effect. With kidney-warming, yang-invigorating, blood-nourishing, blood-activating, meridian-unblocking, and collateral-activating effects of the medicine, kidney yang deficiency is treated, and cough-relieving and asthma-relieving functions are provided. The medicine has a significant effect on asthma patients, and has wide-spectrum practicality.
The present invention discloses a storage device comprising a base box, a box lid, a bottom plate, a set of partitions installed within the base box and dividing it into multiple smaller spaces, a transmitting unit assembly consisting of multiple transmitting units installed within each of the divided small spaces of the base box for generating detection signals, a receiving unit assembly consisting of multiple receiving units installed within the base box corresponding in pairs with the transmitting units, a microswitch detection device used for detecting the opening motion of the box lid of each compartment or the entire box and sending signals to a processor unit, a processor unit used for receiving signals sent by the microswitch detection device or messages sent by a network unit, processing the messages and providing responses, a communication unit used for sending and receiving communication signals, and a warning unit including a monitoring device. The warning unit is capable of sending warning signals and activating the monitoring device at the same time, which can provide images through the communication unit. When the box lid is opened, the microswitch detection device detects the opening of the box lid and sends a signal to the processor unit. After receiving the signal, the processor unit processes and generates corresponding signals, which are then sent to the communication unit to send messages to the user. Upon receiving the signal, the user can connect to the monitoring device via the communication unit and check the status of the medicines in the box being taken. At the same time, the processor notifies the transmitting unit assembly and the receiving unit assembly to send detection signals and reception signals to the processor unit for determining whether the medicines have been taken correctly.
Isolated distal deep vein thrombosis (DVT) represents up to 50% of all lower limb DVT in ultrasound series and is a frequent medical condition, which management is not well established. Data arising from registries and non-randomized studies suggest that most distal DVTs do not extend to the proximal veins and have an uneventful follow-up when left untreated. This data had some impact on international recommendations like the American College of Chest Physicians (ACCP), whose last version stated that ultrasound surveillance might be an option for selected low-risk patients. However, robust data arising from randomized studies are scarce. Indeed, only seven randomized trials assessing the need for anticoagulation for calf DVT have been published. Many of these trials had an open-label design and were affected by methodological limitations. When considering randomized placebo-controlled trials, one included low-risk patients and was hampered by a limited statistical power (CACTUS study). Nevertheless, data from this trial tend to confirm that the use of therapeutic anticoagulation in low-risk patients with symptomatic calf DVT is not superior to placebo in reducing VTE but is associated with a higher risk of bleeding. A second randomized placebo-controlled trial did not assess the necessity of anticoagulant treatment but rather the long-term risk of recurrence and compared 6 weeks versus 12 weeks of treatment with rivaroxaban (RIDTS study). Finally, the last available randomized trial compared a 3-month versus a 12-month edoxaban treatment in patients with cancer and mainly asymptomatic distal DVT, detected by systematic compression ultrasonography. Overall, available data suggest that the use of therapeutic anticoagulation in low-risk patients with symptomatic calf DVT is not superior to placebo in reducing VTE. High risk patients (previous VTE, active cancer, inpatients) might benefit from a course of anticoagulant treatment. However, the optimal anticoagulant intensity and duration are uncertain and further studies are needed.
Cases of thrombotic microangiopathy (TMA), including hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP), have been reported in patients treated with tacrolimus. TMA may have a multifactorial etiology. Risk factors for TMA that can occur in transplant patients include, for example, severe infections, graft-versus-host disease (GVHD), Human Leukocyte Antigen (HLA) mismatch, the use of calcineurin inhibitors and mammalian target of rapamycin (mTOR) inhibitors. These risk factors may, either alone or combined, contribute to the risk of TMA.

In patients with signs and symptoms of TMA, consider tacrolimus as a risk factor. Concurrent use of tacrolimus and mTOR inhibitors may contribute to the risk of TMA.